Zacks: Brokerages Expect Mallinckrodt PLC (NYSE:MNK) to Post $2.05 Earnings Per Share

Share on StockTwits

Equities analysts predict that Mallinckrodt PLC (NYSE:MNK) will report earnings of $2.05 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Mallinckrodt’s earnings, with the lowest EPS estimate coming in at $1.95 and the highest estimate coming in at $2.09. Mallinckrodt reported earnings per share of $2.18 during the same quarter last year, which suggests a negative year over year growth rate of 6%. The firm is expected to announce its next earnings results on Tuesday, February 25th.

On average, analysts expect that Mallinckrodt will report full-year earnings of $8.59 per share for the current fiscal year, with EPS estimates ranging from $8.50 to $8.64. For the next year, analysts anticipate that the firm will report earnings of $6.85 per share, with EPS estimates ranging from $5.46 to $7.76. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Mallinckrodt.

MNK has been the subject of a number of analyst reports. ValuEngine upgraded shares of Mallinckrodt from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Wells Fargo & Co reiterated a “hold” rating on shares of Mallinckrodt in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $8.64.

NYSE MNK opened at $4.49 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.86 and a debt-to-equity ratio of 1.64. Mallinckrodt has a 1-year low of $1.43 and a 1-year high of $27.33. The company has a 50 day moving average of $4.41 and a 200-day moving average of $3.69. The company has a market cap of $414.58 million, a price-to-earnings ratio of 0.57, a PEG ratio of 0.06 and a beta of 2.65.

A number of institutional investors and hedge funds have recently made changes to their positions in MNK. Creative Planning increased its holdings in shares of Mallinckrodt by 129.7% during the fourth quarter. Creative Planning now owns 845,088 shares of the company’s stock worth $2,949,000 after buying an additional 477,200 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Mallinckrodt during the third quarter worth $460,000. California State Teachers Retirement System increased its holdings in shares of Mallinckrodt by 8.4% during the third quarter. California State Teachers Retirement System now owns 152,945 shares of the company’s stock worth $369,000 after buying an additional 11,908 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Mallinckrodt by 76.8% during the third quarter. SG Americas Securities LLC now owns 282,482 shares of the company’s stock worth $681,000 after buying an additional 122,699 shares in the last quarter. Finally, Lincoln Capital Corp acquired a new position in shares of Mallinckrodt during the third quarter worth $48,000. Institutional investors and hedge funds own 91.63% of the company’s stock.

About Mallinckrodt

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Further Reading: Guidelines for Successful Channel Trading

Get a free copy of the Zacks research report on Mallinckrodt (MNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.